New research has demonstrated the potential for the ADDomer platform to produce thermostable vaccines and reagents to tackle viral infections The study led by the University of Bristol and Imophoron, a biopharmaceutical company developing thermostable nanoparticle vaccines using its ADDomer platform, is published in Antibody Therapeutics today (Nov. 29) under the title "In vitro generated antibodies guide thermostable ADDomer nanoparticle design for nasal vaccination and passive immunization against SARS-CoV-2."
